Report Description of the South Africa Oncology Drugs Market
Research Scope and Assumption
- The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
- The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
- We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
- All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
- Inflation has not been accounted for in order to estimate and forecast the market
- Numbers may not add up due to rounding off
- To analyze and forecast the market size of South Africa Oncology Drugs Drugs market
- To classify and forecast South Africa Oncology Drugs Market market based on application, drugs, project type, and application.
- To identify drivers and challenges for South Africa Oncology Drugs market
- To examine competitive developments such as mergers and acquisitions, agreements, collaborations and partnerships, etc., in South Africa Oncology Drugs market
- To conduct pricing analysis for South Africa Oncology Drugs Drugs market
- To identify and analyze the profile of leading players operating in South Africa Oncology Drugs market
Reason to buy the report:
- Facilitate decision-making based on strong current and forecast data for Atopic Dermatitis drug market
- Develop strategies based on the latest regulatory framework
- Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
- Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Atopic Dermatitis market
- Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
- To strategically profile key players and comprehensively analyze their market shares and core competencies
- We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis
South Africa Oncology Drugs Market Executive Summary
Cancer affects one in four South Africans, cancer mortality rates are expected to increase in developing countries. South Africa creating demand for anti-cancer drugs hence leading to the growth of the market.
Market Size and Key Findings
The South Africa Oncology Drugs market size is at around USD xx billion in 2021 and is projected to reach USD xx billion in 2028, exhibiting a CAGR of xx% during the forecast period.
Nearly 8% of the total deaths in South Africa in 2014 were attributed to cancer. Western Cape Province had the highest age standardized cancer mortality rate in South Africa (118, 95% CI: 115–121 deaths per 100 000 individuals). Therefore, the increasing prevalence of cancer is expected to boost the demand for the global oncology cancer drugs market during the forecast period.
Market Growth Drivers Analysis
The rise in incidence and prevalence of various cancer types, new cancer treatments, and the growing importance of biological and targeted drug therapies are certain factors that drive the market growth of South Africa oncology/anti-cancer drugs at present. In addition, an increase in demand for anti-cancer drugs for the treatment of ageing population, the hike in government funding, and improved post-treatment results for advanced therapeutic modalities are the major factors that boost the market growth
The high costs associated with new drug development procedures, coupled with the threat of failure in deriving successful results, and the adverse effects associated with anti-cancer drugs therapies are expected to restrain the growth of the market
COVID-19 impact on “South Africa Oncology Drugs Market”
COVID-19 pandemic has impacted the most crucial areas of the oncology drugs market. Pandemic has directly affected the supply of oncology drugs to cancer patients; not only is it difficult to administer chemotherapy and certain other treatments outside of a clinic, but the spread of coronavirus has reduced patients’ willingness and ability to access not just treatments, but trials for new medicines. COVID-19’s interference with the research and development of new treatments is one of the most significant blows that has been dealt to the oncology drugs market. However, this situation is expected to change post COVID-19 pandemic in the coming years.
Key participants operating in the South Africa Oncology Drug market include Eurolab,Key Oncologics (Pty) Ltd, Pfizer, Roche, Aspen AstraZeneca, AbbVie Inc.,Novartis AG and Others
Products in Pipeline
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. Oncology sales now comprise around 35% of total product sales for AstraZeneca. It has some high-profile cancer drugs in its portfolio like Tagrisso, Lynparza, Faslodex and Imfinzi, which are among its top medicines.
Notable Recent Deals
The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan Africa and Asia. Purchasers are expected to save an average of 59 percent for medicines procured through the agreements.Medications included in the agreements cover recommended regimens for 27 types of cancer and enable complete chemotherapy regimens for the three cancers that cause the most deaths in Africa—breast, cervical, and prostate. These cancers are highly treatable and account for 38 percent of cancers in the countries covered in the agreements.
Healthcare Policies and Regulatory Landscape
Policy changes and Reimbursement scenario of South Africa Oncology Drugs Services
In responding to the high burden of disease among South African women, policies on breast cancer and cervical cancer were approved in 2017. The issuing of regulation 380 of the National Health Act of 2003 in 2011 formally established the National Cancer Registry (NCR) and made compulsory registration of confirmed cancer diagnosis in the country obligatory. This enabled significant improvements in the reporting on cancer through the NCR